Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine

by Zacks Equity Research

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.

Zacks Equity Research

Axsome Expedites Completion Timeline of AD Study on AXS-05

by Zacks Equity Research

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

Zacks Equity Research

Moderna (MRNA) Stock Moves -0.46%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $28.14, marking a -0.46% move from the previous day.

Zacks Equity Research

Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group

by Zacks Equity Research

The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

Zacks Equity Research

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

Zacks Equity Research

Roche to Evaluate Actemra for Severe COVID-19 Pneumonia

by Zacks Equity Research

Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

Debanjana Dey headshot

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

by Debanjana Dey

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Ekta Bagri headshot

Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?

by Ekta Bagri

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Zacks Equity Research

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.